Innocare Pharma's ICP-B381 Wins NMPA Approval for Clinical Trials

Innocare Pharma said on September 9 that its independently developed bispecific ADC drug ICP-B381, which targets PSMA and STEAP1, has been approved by China's National Medical Products Administration's Center for Drug Evaluation to begin clinical trials for prostate cancer and other solid tumors. Jiemian News reported that this is the company's first bispecific ADC to enter the clinical stage and its third ADC innovation drug to move into clinical development. The rest of the source was a market commentary and ETF performance update that focused on Hong Kong innovative drug stocks and was not included.